Dallas
, Texas
- D. Anderson Company (DAC), an international patient recruitment and retention leader based in Dallas, posted a record first quarter on many fronts, including earnings, new business and requests for proposals. The privately held company, whose clientele is a who's who in pharmaceuticals and biotechnology, enters the second quarter brimming with optimism as contracts continue to outpace previous years.
Central to DAC's success is its growth in global markets and its ability to leverage 18 years of experience, including tenure as a Site Management Organization, niche Contract Research Organization and clinical trials recruitment provider.
"In 2007 and 2008, the percent of DAC's business with international focus was 40 and 48 percent respectively for the entire year," said DAC President and CEO Diana Anderson, Ph.D. "Already, in 2009, half of new contracts are for global programs, with the remaining focused on North America. Large pharmaceutical companies represent 66 percent of new business so far this year."
Dr. Anderson has positioned DAC as an international player with experience in 62 countries and expertise in more than 40 therapeutic areas. The company has strong roots in rheumatology but, today, draws most of its business from the oncology, cardiovascular, central nervous system, and immunology sectors.
DAC services include patient recruitment and retention, consulting, management, market research and customized training. With its full-service, in-house creative agency, DAC also combines messaging, design and branding to produce acclaimed marketing concepts.
About D. Anderson Company
With offices in Seattle, Houston and Dallas, DAC is a subsidiary of D.L. Anderson International. The company is certified as a Women-Owned Business (WBE) by the Women's Business Enterprise National Council and a continuing education provider through the California Board of Registered Nursing. For more information, visit
www.dandersoncompany.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.